Online inquiry

IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9401MR)

This product GTTS-WQ9401MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PTPRC gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Mus musculus
RefSeq NM_001267798.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5788
UniProt ID P08575
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9401MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1728MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ADC-1013
GTTS-WQ7450MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ10861MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ4014MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ8355MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA hPAM4
GTTS-WQ12452MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ4321MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ14355MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG7716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW